Human Cytochrome P450 2C9(CYP2C9) ELISA kit

Instructions
Code CSB-EL006419HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name cytochrome P450, family 2, subfamily C, polypeptide 9
Alternative Names (R)-limonene 6-monooxygenase ELISA Kit; (S)-limonene 6-monooxygenase ELISA Kit; (S)-limonene 7-monooxygenase ELISA Kit; CP2C9_HUMAN ELISA Kit; CPC9 ELISA Kit; CYP2C ELISA Kit; CYP2C10 ELISA Kit; CYP2C9 ELISA Kit; CYPIIC9 ELISA Kit; cytochrome P-450 S-mephenytoin 4-hydroxylase ELISA Kit; Cytochrome P-450MP ELISA Kit; Cytochrome P450 2C9 ELISA Kit; Cytochrome P450 MP-4 ELISA Kit; Cytochrome P450 MP-8 ELISA Kit; Cytochrome P450 PB-1 ELISA Kit; Cytochrome P450; family 2; subfamily C; polypeptide 9 ELISA Kit; Cytochrome p4502C9 ELISA Kit; flavoprotein-linked monooxygenase ELISA Kit; MGC149605 ELISA Kit; MGC88320 ELISA Kit; microsomal monooxygenase ELISA Kit; OTTHUMP00000020135 ELISA Kit; P450 MP ELISA Kit; P450 PB 1 ELISA Kit; P450 PB1 ELISA Kit; P450IIC9 ELISA Kit; P450MP ELISA Kit; S mephenytoin 4 hydroxylase ELISA Kit; S-mephenytoin 4-hydroxylase ELISA Kit; xenobiotic monooxygenase ELISA Kit
Abbreviation CYP2C9
Uniprot No. P11712
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 23.5 pg/mL-1500 pg/mL
Sensitivity 5.8 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cardiovascular
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<10%        
Three samples of known concentration were tested in twenty assays to assess.      
               
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human CYP2C9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:1 Average % 105    
Range % 94-109    
1:2 Average % 97    
Range % 89-101    
1:4 Average % 93    
Range % 83-98    
1:8 Average % 107    
Range % 94-111    
Recovery
The recovery of human CYP2C9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
 
Sample Type Average % Recovery Range    
Serum (n=5) 91 81-94    
EDTA plasma (n=4) 105 97-109    
               
               
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
 
pg/ml OD1 OD2 Average Corrected    
1500 2.497 2.389 2.443 2.277    
750 1.795 1.767 1.781 1.615    
375 1.076 1.062 1.069 0.903    
187.5 0.605 0.595 0.600 0.434    
94 0.376 0.366 0.371 0.205    
47 0.248 0.258 0.253 0.087    
23.5 0.215 0.211 0.213 0.047    
0 0.169 0.163 0.166      
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 7-14 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics
Gene References into Functions
  1. Molecular dynamics simulations performed for the active species of the enzyme (heme in the Compound I state), in the apo or substrate-bound state, and binding energy analyses gave insights into altered protein structure and dynamics involved in the defective drug metabolism of human allelic variant CYP2C9*30 (A477T). PMID: 29746595
  2. Lower expression of CYP2C9 was associated with better overall survival and disease-free survival in Hepatocellular carcinoma tumor samples. PMID: 29974848
  3. A significant association between CYP2C9*3 and phenytoin-induced Stevens-Johnson syndrome was identified, especially in a Thai population (Meta-Analysis) PMID: 29274302
  4. In this study, we showed that patients with VKORC1-1639GA and CYP2C9*1/*1 alleles have lower sensitivity for warfarin than those with VKORC1-1639AA and CYP2C9*1/*1 alleles. PMID: 29781049
  5. Enzyme phenotyping with correlation analysis confirmed the predominant role of CYP2C9 in the biotransformation of siponimod and demonstrated the functional consequence of CYP2C9 genetic polymorphisms and fluconazole on siponimod metabolism. PMID: 29273968
  6. Comparisons of pharmacokinetics of 25 substrates CYP2C9, CYP2C19, or CYP2D6 in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C19 = cytochrome P450 family 2 subfamily C member 19; CYP2D6 = cytochrome P450 family 2 subfamily D member 6) PMID: 29181698
  7. genetic association studies in population in Scotland: data suggest, in type 2 diabetes treated with sulfonylureas, 2 SNPs in CYP2C9 (CYP2C9*2, R144C, rs1799853; CYP2C9*3, I359L, rs1057910) are associated with drug-induced hypoglycemia; an SNP in POR (POR*28, A503V, rs1057868) is associated with better response to sulfonylureas. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; POR = cytochrome p450 oxidoreductase) PMID: 28656666
  8. The plasma S-warfarin (Cp(S)) time courses following the genotype-based dosing algorithms simulated using the PPK estimates showed African Americans with CYP2C9*1/*1 and any of the VKORC1 genotypes would have an average Cp(S) at steady state 1.5-1.8 times higher than in Asians and whites. PMID: 27503578
  9. The final regression models for White and Black patients (Fig. 1) included age, weight, prosthetic valves, amiodarone use, CYP2C9*3, and VKORC1 3673 G>A genotypes as covariates, whereas possession of CYP2C9*2 and simvastatin use were retained in the final model for White, but not Black patients. PMID: 28263279
  10. Our results further support a minor contribution of CYP2C9 genetic variability toward steady-state endoxifen concentrations. Integration of clinician and genetic variables into individualized tamoxifen dosing algorithms would marginally improve their accuracy and potentially enhance tamoxifen treatment outcomes. PMID: 28877533
  11. CYP2C9 genetic variation was associated with long-term overall mortality and non-major bleeding in elderly patients treated with vitamin K antagonists. PMID: 28834238
  12. Until the age of 19, weight has a far greater effect on Vitamin K antagonist dosing variation than VKORC1 and CYP2C9 polymorphisms. During the age of 20-40years, VKORC1 and CYP2C9 polymorphisms play a significant role. PMID: 28284562
  13. CYP2C9*3 did show significant effect on warfarin dose requirement PMID: 27313202
  14. Two SNPs in CYP2C9, rs2153628 and rs1799853 are associated with response to indomethacin for the treatment patent ductus arteriosus. PMID: 28609430
  15. the carriership of individual C and T alleles in the case of CYP2C9*2 gene, as well as A and C for CYP2C9*3 is not a predictor of antiretroviral drug-induced liver injury. PMID: 29787666
  16. Genetic polymorphisms in CYP2C9 cause significant interindividual variability in the metabolism of its substrates. This study estimated the coefficient of variation (CV) for the intrinsic hepatic clearance of tolbutamide by CYP2C9 for each CYP2C9 genotype using previously reported area under the blood concentration curve (AUC) and oral clearance (CLoral) values in a Monte Carlo simulation with a dispersion model. PMID: 28435143
  17. These results suggest that genetic polymorphisms of CYP2C9 enzymes result in the production of varying levels of biologically active JWH-018 metabolites in some individuals, offering a mechanistic explanation for the diverse clinical toxicity often observed following JWH-018 abuse. PMID: 29522717
  18. Studied the association of CYP2C9*2 (430C/T), *3 (1075A/C) and VKORC1 (-1639G/A) polymorphisms on warfarin dose requirements in patients post cardiac valve surgery. Found age and presence of CYP2C9 *2 allele significantly affect the daily dosage of warfarin during initiation of warfarin therapy after cardiac valve replacement surgery. PMID: 29182754
  19. CYP2C9 mutations had a significant impact on 2-propyl-4-pentenoic acid concentration PMID: 28315807
  20. Angiotensin II receptor blockers exhibit different degrees of inhibition of the metabolism of arachidonic acid by recombinant CYP2C9, CYP2J2 and liver microsomes. PMID: 28374982
  21. analysis of VKORC1 AA-CYP2C9*1*1 genotypes reveals dosing algorithms for vitamin K antagonists PMID: 28063245
  22. To investigate whether the CYP2C9*2 and *3 variants modify benzodiazepine-related fall risk. CYP2C9*2 and *3 allele variants modify benzodiazepine-related fall risk. Those using benzodiazepines and having reduced CYP2C9 enzyme activity based on their genotype are at increased fall risk. PMID: 27889507
  23. In an Indian population of children with epilepsy on phenytoin monotherapy, CYP2C9*1, *2 & *3 allelic frequencies were 85.4, 4.5 and 10.1 % respectively. CYP2C9*3 allelic group showed significantly higher serum phenytoin levels compared to the wild variants. PMID: 27179628
  24. The genotype distributions of the CYP2C9*3, CYP2D6*10, and CYP3A5*3 genetic polymorphisms were associated with the warfarin maintenance dose. PMID: 28872889
  25. CYP2C9*2 and CYP2C9*3 genetic polymorphisms are associated with reduced S-warfarin oral clearance in healthy subjects PMID: 27878474
  26. Case Report: time course of CYP2C9 deinduction appeared to be delayed compared to CYP3A after discontinuation of rifampicin therapy. PMID: 28157069
  27. Data suggest that SNPs in CYP2C9 (*3, I359L; *30, A477T) that reduce catalytic activity of CYP2C9 also alter interaction with antihypertensive drug losartan; I359L substitution located far from active site remarkably alters residue side chains near active site and access channel, whereas the T477 substitution illustrates hydrogen-bonding interaction with reoriented side chain of Q214. PMID: 28972767
  28. SNP rs4918758 of CYP2C9 showed a suggestive association with decreased risk of coronary heart disease. PMID: 28687336
  29. CYP2C9*31075AC genotype with combined alcohol and nevirapine usage indicated a risk for development of antiretroviral-associated hepatotoxicity PMID: 28370504
  30. CYP2C9 polymorphisms showed no effect on PC doses. Similar findings were observed in the initiation phase of PC therapy. High complications rates under PC therapy were observed particularly at the beginning. PMID: 26984978
  31. Genetic variants of CYP2C9/VKORC1 and age are significant determinants of the maintenance dose of warfarin in patients with atrial fibrillation/valve replacement. PMID: 27117036
  32. CYP2C9*3 polymorphism genotype and allele frequency were not statistically different between the case and control Ankylosing Spondylitis groups (P>0.05). the efficacy of NSAID in treatment of AS and COX-2 gene -1290A/G and -1195G/A polymorphism were associated (all P<0.05), but it is not associated with CYP2C9 *3 polymorphism (all P>0.05). PMID: 28403136
  33. polymorphisms c.98T>C in the UGT1A9 and c.1075A>C in the CYP2C9 genes did not affect the pharmacokinetic profile of propofol PMID: 27826892
  34. Possession of CYP2C9*2 and/or CYP2C9*3 allele variants is associated with lower time of international normalized ratio (INR) in the therapeutic range (TTR) values and warfarin dose variations in aortic valve replacement patients, the latter affected also by VKORC1 c.-1693G>A polymorphism PMID: 27511999
  35. Three SNPs (CYP2C9 *2, *3 and VKORC1 c.-1639G > A) were genotyped by electrochemical detection using a sandwich-type format that included a 3' short thiol capture probe and a 5' ferrocene-labeled signal probe. PMID: 28083852
  36. Two subjects with CYP2C9PM genotype both showed markedly higher AUC, prolonged half-life, and lower CL/F for celecoxib than did subjects with CYP2C9EM and IM genotypesTwo subjects with CYP2C9PM genotype both showed markedly higher AUC0-infinity, prolonged half-life, and lower CL/F for celecoxib than did subjects with CYP2C9EM and IM genotypes PMID: 27864660
  37. CYP2C9 IVS8-109 T carriers showed significantly higher dose-corrected phenoytoin blood concentrations and this allele was found in a higher frequency in epileptic patients with supratherapeutic phenytoin levels. PMID: 26122019
  38. Med25, a variable member of the Mediator complex, is a coactivator of ligand-activated ERalpha that interacts with ERalpha through its C-terminal LXXLL motif after BPA exposure, and is functionally involved in BPA-induced transcriptional regulation of CYP2C9 expression and enzyme activity. PMID: 27273787
  39. Our results show that anticoagulated patients have a high risk of adverse events if they are carriers of 1 or more genetic polymorphisms in the VKORC1 (rs9923231) and CYP2C9 (rs1799853 and rs1057910) genes. PMID: 28033245
  40. Review/Meta-analysis: CYP2C9 gene polymorphism was significantly associated with decreased warfarin maintenance dose requirements in pediatric patients. PMID: 27661060
  41. The intrinsic clearance (Vmax/Km) values of all variants, with the exception of CYP2C9*2, CYP2C9*11, CYP2C9*23, CYP2C9*29, CYP2C9*34, CYP2C9*38, CYP2C9*44, CYP2C9*46 and CYP2C9*48, were significantly different from CYP2C9*1. CYP2C9*27, *40, *41, *47, *49, *51, *53, *54, *56 and N418T variant exhibited markedly larger values than CYP2C9*1. PMID: 27163851
  42. Report roles for CYP3A4 and CYP2C9 in sequential two-step bioactivation of diclofenac to reactive p-benzoquinone imines. PMID: 27130197
  43. CYP2C9*2 and *3 variants were not detected and may not be the most important genetic factor for warfarin maintenance dose among Ghanaians. PMID: 27938396
  44. Cyp2C9 genetic polymorphisms significantly affected the plasma concentrations of zafirlukast. PMID: 27377818
  45. The high frequency of CYP2C9*3 and the absence of CYP2C9*2 in Jahais suggest that genetic drift may be occurring in this ethnic group. PMID: 26402341
  46. VKORC1-CYP2C9 interaction can affect warfarin stable dosage. PMID: 25187307
  47. Results show a statistically significant association between CYP2C9*3 polymorphism and phenytoin-related Stevens-Johnson syndrome. PMID: 26928377
  48. P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects PMID: 26669712
  49. VKORC1S1639 GG and the wild type CYP2C9*1*1 genotypes are associated with the high-dose requirement for warfarin therapy. PMID: 24978953
  50. Patients with variant CYP2C9 are at increased risk for cyclophosphamide-induced leukopenia but may have a better chance to respond to treatment. PMID: 26894931

Show More

Hide All

Subcellular Location Endoplasmic reticulum membrane, Peripheral membrane protein, Microsome membrane, Peripheral membrane protein
Protein Families Cytochrome P450 family
Database Links

HGNC: 2623

OMIM: 601130

KEGG: hsa:1559

STRING: 9606.ENSP00000260682

UniGene: Hs.282624

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1